Retatrutide 10mg

Retatrutide 10mg – Triple GLP-1/GIP/Glucagon Receptor Agonist for Research

Retatrutide 10mg (LY3437943) is an investigational triple receptor agonist developed by Eli Lilly for preclinical and laboratory research. This lyophilized powder format is intended for researchers studying GLP-1 receptor signaling, glucagon receptors, and glucose dependent insulinotropic polypeptide (GIP) receptor pathways simultaneously. Not for human use.

What Is Retatrutide (LY3437943)?

Retatrutide peptide (LY3437943) is a novel investigational compound developed by Eli Lilly that functions as a triple hormone receptor agonist targeting three distinct signaling pathways: the GLP-1 receptor, the glucose dependent insulinotropic polypeptide (GIP) receptor, and glucagon receptors. This unique triple agonist mechanism distinguishes retatrutide from dual-agonist compounds like tirzepatide (which targets GLP-1 and GIP only) by adding glucagon receptor activation to the mix.

For researchers studying metabolic pathways, energy expenditure regulation, and weight loss mechanisms, retatrutide represents a valuable investigational compound. The addition of glucagon receptor agonism to GLP-1 and GIP signaling appears to amplify effects on energy expenditure and body weight regulation observed in preclinical and Phase 2 clinical trial models.

Retatrutide 10mg – Product Specifications

Triple Receptor Mechanism: GLP-1, GIP, and Glucagon Receptors

The defining characteristic of retatrutide is its triple agonist activity at three metabolically important receptors. Understanding each receptor’s role helps researchers appreciate why simultaneous activation may produce distinct downstream effects compared to mono- or dual-agonist compounds.

GLP-1 Receptor Signaling

Glucagon-like peptide-1 (GLP-1) receptor agonism is well-studied in the context of incretin biology. In research models, GLP-1 receptor activation has been associated with increased insulin secretion in response to glucose, reduced gastric emptying, and central nervous system effects on appetite-related signaling. Retatrutide’s GLP-1 receptor component builds on established research foundations while the triple combination creates novel mechanistic opportunities for study.

GIP (Glucose Dependent Insulinotropic Polypeptide) Receptor Signaling

The glucose dependent insulinotropic polypeptide (GIP) receptor pathway adds another incretin dimension to retatrutide research. GIP receptor activation in preclinical models has been associated with enhanced insulin secretory responses and adipose tissue signaling. Research on dual GLP-1/GIP agonists like tirzepatide paved the way for studying how adding a third receptor (glucagon) might further modulate metabolic parameters including weight loss and energy expenditure.

Glucagon Receptor Pathway

Glucagon receptors play a central role in hepatic glucose output and energy expenditure. The inclusion of glucagon receptor agonism in retatrutide’s mechanism is hypothesized to enhance energy expenditure — a key differentiator from GLP-1-only compounds. In Phase 2 clinical research published in the New England Journal of Medicine (Jastreboff et al., 2023), retatrutide research subjects demonstrated substantial changes in body weight metrics, with effects on energy expenditure emerging as a key area of ongoing investigation.